These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33141944)

  • 21. Personality traits and escitalopram treatment outcome in major depression.
    Aluoja A; Tõru I; Raag M; Eller T; Võhma Ü; Maron E
    Nord J Psychiatry; 2018 Jul; 72(5):354-360. PubMed ID: 29688152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A New Prediction Model for Evaluating Treatment-Resistant Depression.
    Kautzky A; Baldinger-Melich P; Kranz GS; Vanicek T; Souery D; Montgomery S; Mendlewicz J; Zohar J; Serretti A; Lanzenberger R; Kasper S
    J Clin Psychiatry; 2017 Feb; 78(2):215-222. PubMed ID: 28068461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
    Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
    JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR; Huang H; Thase ME
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample.
    Kautzky A; Dold M; Bartova L; Spies M; Vanicek T; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fabbri C; Serretti A; Lanzenberger R; Kasper S
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29228516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressants for the treatment of depression in people with cancer.
    Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011006. PubMed ID: 26029972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
    Ruhé HG; Huyser J; Swinkels JA; Schene AH
    J Clin Psychiatry; 2006 Dec; 67(12):1836-55. PubMed ID: 17194261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors.
    Papakostas GI; Fan H; Tedeschini E
    Eur Neuropsychopharmacol; 2012 May; 22(5):347-55. PubMed ID: 22099607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
    Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
    Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report.
    Braund TA; Palmer DM; Williams LM; Harris AW
    Aust N Z J Psychiatry; 2019 Aug; 53(8):782-793. PubMed ID: 30880405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.